Bing Yao, ArriVent Biopharma CEO
January 3, 2023 08:49 AM ESTUpdated 11:13 AM
Financing
Startups
China

Scoop: Bing Yao’s Ar­riVent lin­ing up $145M raise, af­ter $150M de­but in 2021

Kyle LaHucik

Senior Reporter

Bing Yao took his pre­vi­ous biotech through three key mile­stones: IPO, drug ap­proval and an M&A ex­it. Now, he’s lin­ing up an­oth­er round of fi­nanc­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

A service from the Financial Times